Federal Register / Vol. 71, No. 169 / Thursday, August 31, 2006 / Notices 51835 

Covell, WG Rice, E Appella. Synthesis 

and biological properties of novel 

pyridinioalkanoyl thiolesters (PATE) as 

anti-HIV–1 agents that target the viral 

nucleocapsid protein zinc fingers. J Med 

Chem. 1999 Jan 14;42(1):67–86. 

Patent Status: U.S. Patent Application 

No. 10/485,165 filed 28 Jan 2004, 

claiming priority to 03 Aug 2001 (HHS 

Reference No. E–329–2000/0–US–06). 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Sally H. Hu, Ph.D., 

M.B.A.; 301/435–5605; 

hus@mail.nih.gov. 

Novel Thioesters and Uses Thereof 

Description of Technology: The 

human immunodeficiency virus (HIV) is 

the causative agent of acquired 

immunodeficiency syndrome (AIDS). 

Drug-resistance is a critical factor 

contributing to the gradual loss of 

clinical benefit to treatments for HIV 

infection. Accordingly, combination 

therapies have further evolved to 

address the mutating resistance of HIV. 

However, there has been great concern 

regarding the apparent growing 

resistance of HIV strains to current 

therapies. 

The present invention provides for a 

novel family of thioesters and uses 

thereof. These thioesters are capable of 

inactivating viruses by a variety of 

mechanisms, particularly by 

complexing with metal ion-complexing 

zinc fingers. The invention further 

provides for methods for inactivating a 

virus, such as the human 

immunodeficiency virus (HIV), using 

these compounds, and thereby also 

inhibiting transmission of the virus. 

Inventors: James A. Turpin (NCI), 

Yongsheng Song (NCI), John K. Inman 

(NIAID), Mingjun Huang (NCI), Anders 

Wallqvist (NCI), David G. Covell (NCI), 

William G. Rice (NCI), Ettore Appella 

(NCI), et al. 

Patent Status: U.S. Patent No. 

6,706,729 issued 16 Mar 2004 (HHS 

Reference No. E–136–1998/0–US–10); 

U.S. Patent Application No. 10/738,062 

filed 16 Dec 2003 (HHS Reference No. 

E–136–1998/0–US–11). 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Sally H. Hu, Ph.D., 

M.B.A.; 301/435–5605; 

hus@mail.nih.gov. 

Dated: August 25, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 06–7327 Filed 8–30–06; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

A Novel Small Protein Antibiotic 

Description of Technology: Due to the 

increase in drug resistance among 

bacteria, continued progress in the 

development of new antibiotic 

treatments is needed. Available for 

licensing and commercial development 

is the small protein SrgT, its analogs 

and related peptides. SrgT is a 43 amino 

acid protein that effectively inhibits 

bacterial growth. This protein likely 

exerts its antibiotic action by inhibiting 

the metabolism of glucose in these 

microorganisms. The claimed invention 

includes methods for SrgT synthesis 

and suggested modifications for 

production of SrgT analogs and related 

peptides, which may remain effective 

against potential SrgT resistant bacteria. 

Thus, the current technology provides a 

novel approach to the treatment and 

prevention of bacterial infections. 

Application: Novel therapeutics and 

prophylactics for bacterial infections. 

Development Status: Preclinical data 

is available at this time. 

Inventors: Carin K. Vanderpool and 

Susan Gottesman (NCI). 

Selected Publication: CK Vanderpool, 

S Gottesman. Involvement of a novel 

transcriptional activator and small RNA 

in post-transcriptional regulation of the 

glucose phosphoenolpyruvate 

phosphotransferase system. Mol 

Microbiol. 2004 Nov; 54(4):1076–1089. 

Patent Status: U.S. Provisional 

Application No. 60/799,830 filed 11 

May 2006 (HHS Reference No. E–166–

2006/0–US–01). 

Licensing Status: Available for nonexclusive and exclusive licensing. 

Licensing Contact: Cristina 

Thalhammer-Reyero, Ph.D., M.B.A.; 

301/435–4507; thalhamc@mail.nih.gov. 

Methods and Compositions for the 

Production of Highly Effective Vaccines 

Against Cancers and Infections 

Diseases 

Description of Technology: Because 

cancers and infectious diseases remain 

prominent causes of death among adults 

and children worldwide, the availability 

of vaccines targeting these conditions is 

a global health priority. With the current 

vaccine development state-of-the-art, 

there are limitless combinations of 

enhancing molecules that can be used 

with antigen vaccines targeting these 

diseases. The technology offered for 

licensing and commercial development 

combines effective aspects of antigenvaccines, including peptides and other 

forms of vaccination, with enhancing 

molecules, including co-stimulation of 

T cell immunity for efficient vaccine 

development. 

The claimed invention includes a 

non-viral polynucleotide vector 

encoding immune enhancing molecules, 

such as the T cell co-stimulatory 

molecule B7.1 (CD80), which 

significantly enhance cellular immune 

responses when combined with antigen 

stimulation. Delivery of this costimulatory molecule as non-replicating 

DNA with any antigenic form, peptides 

in this case, overcomes the problems of 

combining enhancing molecules with 

the antigen in the same DNA vector, coinfecting or transfecting these molecules 

in the same antigen presenting or tumor 

cell, or manufacturing enhancing 

molecules in the same format as the 

antigens. Furthermore, the use of this 

chimeric vaccine with the enhancing 

molecule expressed as polynucleotide 

vector overcomes the low antigenicity 

and safety considerations of viral 

vectors, as well as the instability and 

conformational maintenance challenges 

associated with the use of full-length 

protein delivery. Furthermore, 

polynucleotide’s constructs encoding 

enhancing molecules are inexpensive to 

produce and can potentially be used 

along with any form of antigen vaccine 

delivery system, including peptides, 

full-length proteins and naked DNA 

antigens. 


erjones on PROD1PC72 with NOTICES
51836 Federal Register / Vol. 71, No. 169 / Thursday, August 31, 2006 / Notices 

Applications: (1) Significant 

enhancement of immunological 

responses to antigen vaccines; (2) 

Development of safe and effective 

vaccines for cancer and various 

infectious diseases; (3) Cost effective 

vaccine to test the combination of 

immune enhancing molecules with any 

form of antigen vaccine. 

Development Status: Preclinical data 

is available at this time. 

Inventors: Samir Khleif and Jay 

Berzofsky (NCI). 

Patent Status: U.S. Patent Application 

No. 09/810,310 filed 14 Mar 2001 (HHS 

Reference No. E–128–2000/0-US–02). 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Cristina 

Thalhammer-Reyero, Ph.D., M.B.A.; 

301/435–4507; thalhamc@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute Vaccine 

Branch is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize methods and 

compositions for the production of 

highly effective vaccines. Please contact 

Betty Tong, Ph.D., at 301–594–4263 or 

tongb@mail.nih.gov for more 

information. 

Dated: August 25, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 06–7329 Filed 8–30–06; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

The Mucus Slurper: A Novel Device to 

Keep the Endotracheal Tube (ETT) Free 

of all Mucus, Without Suctioning. 

Description of Technology: Available 

for licensing and commercial 

development is a mucus slurping device 

to remove all mucus, before mucus 

reaches the tip of the endotracheal tube 

(ETT); thus, no mucus ever enters the 

ETT, and the ETT remains always 

clean—without suctioning. A 

Mallinckrodt Hi-Lo CASS (continuous 

aspiration of subglottic secretions) 

endotracheal tube is modified by 

appending to the distal-most tip of a 

cut-off CASS tube a molded, hollow, 

concentric plastic ring with 3–4 (or 

more) small (less than 1 mm in 

diameter) suction ports, the latter 

positioned in the most dependent part 

of the ETT (Figure 1). The CASS line 

was extended to the very tip of the ETT, 

and suction was activated for 

approximately 0.5 s, synchronized to 

the early part of expiration; and 

repeated once a minute, or as desired. 

All mucus was collected in a small inline vial. Healthy, anesthetized and 

paralyzed sheep, were intubated with a 

modified 8 mm CASS ETT tube with 

attached ‘‘Mucus Slurper’’; with sheep 

lying prone, trachea/neck oriented 

below horizontal. Never suctioned. At 

the end of the 72 h study, sheep were 

electively euthanized, and autopsied. 

Figure 1. Normal arterial blood gases. 

No traces of mucus were found along 

the entire length of the ETT. There were 

no gross abnormalities of the tracheal 

mucosa; Bacterial cultures of the 5 lobes 

of the lungs were negative. The Mucus 

Slurper represents a new concept that 

may significantly contribute to 

improved care of patients intubated and 

mechanically ventilated; with no need 

for suctioning/cleaning, and free of 

ventilator associated pneumonia. 

Applications: (1) Prevention of 

ventilator associated pneumonia; (2) 

Intubation; (3) Mucus clearance. 

Market: All patients intubated for 

longer than 18 hours. 

Development Status: Pre-clinical data 

available from sheep. 

Inventors: Theodor Kolobow, 

Gianluigi Li Bassi, Francesco Curto 

(NHLBI). 

Publications: 


erjones on PROD1PC72 with NOTICESEN31AU06.036</GPH>